CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 427 enrolled
Drug / intervention
BIA 9-1067 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01227655
NCT01227655Phase 3Completed
CompareCT.gov

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Study.

Bial - Portela C S.A.·interventional·Posted Oct 25, 2010·Updated Oct 19, 2015

In Brief

A Phase 3 clinical trial evaluating BIA 9-1067, Placebo, and 3 other interventions for Parkinson's Disease. Completed, enrolled 427 participants across 1 site.

Detailed Summary

Parkinson's disease (PD) is a neurodegenerative disorder of unknown aetiology with an estimated incidence of 4.5-16/100,000 persons/year. BIA 9-1067 is currently being developed by BIAL (Portela \& Cª,S.A.) to be used in addition to L-DOPA (Levodopa) /carbidopa or L-DOPA (Levodopa) / preparations in PD patients. Promising results have been obtained for BIA 9-1067 in previous studies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesPortugal
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 25, 2010
Enrollment StartMar 1, 2011
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.7 years ago

Interventions

BIA 9-1067drug

Capsules will be used.

Placebodrug

comparator

Levodopadrug

Carbidopadrug

DOPA decarboxylase inhibitor (DDCI)

Benserazidedrug

DOPA decarboxylase inhibitor